Curr Opin Oncol：晚期前列腺癌多方面药物的组合以及排序治疗

2015-03-31 范伟译 MedSci原创

评审目的:多个具有非常不同的作用机制和独特的毒副作用和功效的药物常常被用于晚期前列腺癌的治疗。下一波的研究重点是对当前可用的药物进行组合以及最优化的排序。本文的重点是提供过去一年临床晚期前列腺癌治疗的更新数据,指出正在进行研究的有前景的新靶点以及新化合物。最近发现: 在转移性阉割抵抗的前列腺癌中，与安慰剂组相比，先于化疗的恩杂鲁胺的临床使用表明无进展生存期和总生存期有改善。恩杂鲁胺化疗抵抗的男

评审目的:多个具有非常不同的作用机制和独特的毒副作用和功效的药物常常被用于晚期前列腺癌的治疗。下一波的研究重点是对当前可用的药物进行组合以及最优化的排序。本文的重点是提供过去一年临床晚期前列腺癌治疗的更新数据,指出正在进行研究的有前景的新靶点以及新化合物。

最近发现: 在转移性阉割抵抗的前列腺癌中，与安慰剂组相比，先于化疗的恩杂鲁胺的临床使用表明无进展生存期和总生存期有改善。恩杂鲁胺化疗抵抗的男性转移性前列腺癌的试验报告而使美国食品和药品监督管理局批准该药剂。新药卡博替尼和库司替森在II期临床试验中显示有前景的结果，却在III期临床阶段显示令人失望的结果。突破性报告表明,雄激素受体剪接变体突变的功能在循环肿瘤细胞中检测到, 对基因1和2(BRCA1/2)突变的前列腺癌和乳腺癌，预测对阿比特龙或恩杂鲁胺没有反应,对聚(ADP-ribose)聚合酶抑制剂有明显的反应,在生物标记物-驱动的治疗领域具有光明的前景。

总结:随着最近批准的多方面疗法临床应用的扩大,试验探寻药物最优排序和组合越来越重要。此外,探索激素抵抗疗法或非转移性阶段的实用疗法是活跃的研究领域。早期可用性药物的使用,药物最优化的排序和生物标志物的辅助指导着治疗的选择性，这也将使晚期前列腺癌获得生命周期的缓解成为可以达到的目标。

原始出处

Vaishampayan UN1. Sequences and combinations of multifaceted therapy in advanced prostate cancer. Curr Opin Oncol. 2015 Mar 25

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1953476, encodeId=ea8419534e687, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Feb 09 12:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24695, encodeId=6fbc246955e, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864631, encodeId=6508186463125, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Aug 04 23:43:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412766, encodeId=c2641412e66cb, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Apr 02 02:43:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
2016-02-09 yangcx0915

#期前列腺癌#

22 0
[GetPortalCommentsPageByObjectIdResponse(id=1953476, encodeId=ea8419534e687, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Feb 09 12:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24695, encodeId=6fbc246955e, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864631, encodeId=6508186463125, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Aug 04 23:43:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412766, encodeId=c2641412e66cb, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Apr 02 02:43:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
2015-05-24 ljjj1053

不错，学习了

73 0
[GetPortalCommentsPageByObjectIdResponse(id=1953476, encodeId=ea8419534e687, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Feb 09 12:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24695, encodeId=6fbc246955e, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864631, encodeId=6508186463125, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Aug 04 23:43:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412766, encodeId=c2641412e66cb, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Apr 02 02:43:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
2015-08-04 minlingfeng

#Oncol#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1953476, encodeId=ea8419534e687, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Tue Feb 09 12:43:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24695, encodeId=6fbc246955e, content=不错，学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sun May 24 12:42:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864631, encodeId=6508186463125, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Aug 04 23:43:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412766, encodeId=c2641412e66cb, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Thu Apr 02 02:43:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
2015-04-02 zhyy89

#晚期前列腺癌#

27 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

Curr Opin Oncol：晚期前列腺癌多方面药物的组合以及排序治疗

相关资讯

科室

工具

服务